May 27, 2025 09:19 AM EDT
Startups
Deals
Pharma

Bio­gen taps City Ther­a­peu­tics in RNAi deal worth up to $1B

Kyle LaHucik

Biotech Correspondent

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.

City will ap­ply its RNAi en­gi­neer­ing chops …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

No­var­tis won bid­ding war for kid­ney drug as Reg­u­lus' top three ex­ecs ex­pect to make over $100M com­bined

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

FDA lead­er­ship preps for sum­mer bio­phar­ma lis­ten­ing tour across six cities

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times